Centre d'Information et de documentation du CRA Rhône-Alpes
CRA
Informations pratiques
-
Adresse
Centre d'information et de documentation
du CRA Rhône-Alpes
Centre Hospitalier le Vinatier
bât 211
95, Bd Pinel
69678 Bron CedexHoraires
Lundi au Vendredi
9h00-12h00 13h30-16h00Contact
Tél: +33(0)4 37 91 54 65
Mail
Fax: +33(0)4 37 91 54 37
-
Résultat de la recherche
8 recherche sur le mot-clé 'psychopharmacology'
Affiner la recherche Générer le flux rss de la recherche
Partager le résultat de cette recherche Faire une suggestion
Psychopharmacology of autism spectrum disorders: A selective review / Sarah MOHIUDDIN in Autism, 17-6 (November 2013)
[article]
Titre : Psychopharmacology of autism spectrum disorders: A selective review Type de document : Texte imprimé et/ou numérique Auteurs : Sarah MOHIUDDIN, Auteur ; Mohammad GHAZIUDDIN, Auteur Année de publication : 2013 Article en page(s) : p.645-654 Langues : Anglais (eng) Mots-clés : autism psychopharmacology comorbidity Index. décimale : PER Périodiques Résumé : While there is no cure for autism spectrum disorder, psychopharmacologic agents are often used with behavioral and educational approaches to treat its comorbid symptoms of hyperactivity, irritability, and aggression. Studies suggest that at least 50% of persons with autism spectrum disorder receive psychotropic medications during their life span. This selective review examines recent studies about the use of psychotropic medications in persons with autism spectrum disorder. The aim was to focus on randomized controlled trials conducted from 1990 to 2010 on this topic. A comprehensive literature search was performed using PubMed and Cochrane databases. Out of 105 studies identified for the review, only 24 were randomized controlled trials. Thus, despite the common use of these medications in autism spectrum disorder, more controlled studies are needed to determine their long-term efficacy and safety. En ligne : http://dx.doi.org/10.1177/1362361312453776 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=218
in Autism > 17-6 (November 2013) . - p.645-654[article] Psychopharmacology of autism spectrum disorders: A selective review [Texte imprimé et/ou numérique] / Sarah MOHIUDDIN, Auteur ; Mohammad GHAZIUDDIN, Auteur . - 2013 . - p.645-654.
Langues : Anglais (eng)
in Autism > 17-6 (November 2013) . - p.645-654
Mots-clés : autism psychopharmacology comorbidity Index. décimale : PER Périodiques Résumé : While there is no cure for autism spectrum disorder, psychopharmacologic agents are often used with behavioral and educational approaches to treat its comorbid symptoms of hyperactivity, irritability, and aggression. Studies suggest that at least 50% of persons with autism spectrum disorder receive psychotropic medications during their life span. This selective review examines recent studies about the use of psychotropic medications in persons with autism spectrum disorder. The aim was to focus on randomized controlled trials conducted from 1990 to 2010 on this topic. A comprehensive literature search was performed using PubMed and Cochrane databases. Out of 105 studies identified for the review, only 24 were randomized controlled trials. Thus, despite the common use of these medications in autism spectrum disorder, more controlled studies are needed to determine their long-term efficacy and safety. En ligne : http://dx.doi.org/10.1177/1362361312453776 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=218 Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder / E. HENNEBERRY in Journal of Autism and Developmental Disorders, 51-12 (December 2021)
[article]
Titre : Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder Type de document : Texte imprimé et/ou numérique Auteurs : E. HENNEBERRY, Auteur ; M. LAMY, Auteur ; K. C. DOMINICK, Auteur ; C. A. ERICKSON, Auteur Article en page(s) : p.4370-4394 Langues : Anglais (eng) Mots-clés : Antipsychotic Agents/therapeutic use Autism Spectrum Disorder/drug therapy Autistic Disorder/drug therapy Humans Irritable Mood Psychopharmacology Anti-psychotic Autism Autism spectrum disorder Drug treatment Irritability Index. décimale : PER Périodiques Résumé : Recent decades have been marked by a wave drug treatment research in autism spectrum disorder (ASD). This work has resulted in improved ability to treat commonly occurring behavioral challenges associated with ASD including most prominently irritability marked by aggression, self-injurious behavior, and severe tantrums. While treatment of interfering behavior has progressed in our field, there remain several areas of unmet medical need including most prominently a lack of any approved drug therapies for the core, defining symptoms of autism. We outline the progress to date in the field of autism drug treatment while taking a future look forward into how decades of work can inform better future steps in this field. En ligne : http://dx.doi.org/10.1007/s10803-021-05237-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=454
in Journal of Autism and Developmental Disorders > 51-12 (December 2021) . - p.4370-4394[article] Decades of Progress in the Psychopharmacology of Autism Spectrum Disorder [Texte imprimé et/ou numérique] / E. HENNEBERRY, Auteur ; M. LAMY, Auteur ; K. C. DOMINICK, Auteur ; C. A. ERICKSON, Auteur . - p.4370-4394.
Langues : Anglais (eng)
in Journal of Autism and Developmental Disorders > 51-12 (December 2021) . - p.4370-4394
Mots-clés : Antipsychotic Agents/therapeutic use Autism Spectrum Disorder/drug therapy Autistic Disorder/drug therapy Humans Irritable Mood Psychopharmacology Anti-psychotic Autism Autism spectrum disorder Drug treatment Irritability Index. décimale : PER Périodiques Résumé : Recent decades have been marked by a wave drug treatment research in autism spectrum disorder (ASD). This work has resulted in improved ability to treat commonly occurring behavioral challenges associated with ASD including most prominently irritability marked by aggression, self-injurious behavior, and severe tantrums. While treatment of interfering behavior has progressed in our field, there remain several areas of unmet medical need including most prominently a lack of any approved drug therapies for the core, defining symptoms of autism. We outline the progress to date in the field of autism drug treatment while taking a future look forward into how decades of work can inform better future steps in this field. En ligne : http://dx.doi.org/10.1007/s10803-021-05237-9 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=454 Psychopharmacologic intervention for adults with autism spectrum disorder: A systematic literature review / Lauren J. TAYLOR in Research in Autism Spectrum Disorders, 25 (May 2016)
[article]
Titre : Psychopharmacologic intervention for adults with autism spectrum disorder: A systematic literature review Type de document : Texte imprimé et/ou numérique Auteurs : Lauren J. TAYLOR, Auteur Article en page(s) : p.58-75 Langues : Anglais (eng) Mots-clés : ASD Adults Psychopharmacology Index. décimale : PER Périodiques Résumé : AbstractBackground The increased recognition of psychiatric and behavioural disorder in adults with autism spectrum disorder (ASD) has been associated with more frequent use of psychopharmacologic intervention in this population. However, limited evidence supports the effectiveness of these interventions for adults with ASD. Objective To review and synthesise the evidence regarding the effectiveness of psychotropic medication in reducing behavioural disturbance in adults with ASD. Data sources and study selection Electronic literature search of PubMed plus manual reference checks of all articles on psychopharmacology in adults with ASD published in the English language between 1985 and 2015. Results and conclusions A total of 43 studies were included in the analysis. The results indicate that only two medications, fluoxetine and risperidone, can be considered as promising evidence-based practices for adults with ASD. Given the rising prevalence of ASD, along with increased use of psychopharmacologic intervention in this population, there is a clear need for methodologically rigorous research to establish the effectiveness of these interventions. The subsequent establishment of clinical guidelines for medication use in this population is essential. En ligne : http://dx.doi.org/10.1016/j.rasd.2016.01.011 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=285
in Research in Autism Spectrum Disorders > 25 (May 2016) . - p.58-75[article] Psychopharmacologic intervention for adults with autism spectrum disorder: A systematic literature review [Texte imprimé et/ou numérique] / Lauren J. TAYLOR, Auteur . - p.58-75.
Langues : Anglais (eng)
in Research in Autism Spectrum Disorders > 25 (May 2016) . - p.58-75
Mots-clés : ASD Adults Psychopharmacology Index. décimale : PER Périodiques Résumé : AbstractBackground The increased recognition of psychiatric and behavioural disorder in adults with autism spectrum disorder (ASD) has been associated with more frequent use of psychopharmacologic intervention in this population. However, limited evidence supports the effectiveness of these interventions for adults with ASD. Objective To review and synthesise the evidence regarding the effectiveness of psychotropic medication in reducing behavioural disturbance in adults with ASD. Data sources and study selection Electronic literature search of PubMed plus manual reference checks of all articles on psychopharmacology in adults with ASD published in the English language between 1985 and 2015. Results and conclusions A total of 43 studies were included in the analysis. The results indicate that only two medications, fluoxetine and risperidone, can be considered as promising evidence-based practices for adults with ASD. Given the rising prevalence of ASD, along with increased use of psychopharmacologic intervention in this population, there is a clear need for methodologically rigorous research to establish the effectiveness of these interventions. The subsequent establishment of clinical guidelines for medication use in this population is essential. En ligne : http://dx.doi.org/10.1016/j.rasd.2016.01.011 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=285 Psychopharmacological treatment of challenging behaviours in adults with autism and intellectual disabilities: A systematic review / Amanda SAWYER in Research in Autism Spectrum Disorders, 8-7 (July 2014)
[article]
Titre : Psychopharmacological treatment of challenging behaviours in adults with autism and intellectual disabilities: A systematic review Type de document : Texte imprimé et/ou numérique Auteurs : Amanda SAWYER, Auteur ; Johanna K. LAKE, Auteur ; Yona LUNSKY, Auteur ; Shi-Kai LIU, Auteur ; Pushpal DESARKAR, Auteur Article en page(s) : p.803-813 Langues : Anglais (eng) Mots-clés : Autism Adults Challenging behaviours Psychopharmacology Intellectual disability Index. décimale : PER Périodiques Résumé : AbstractIntroduction Autism is a neurodevelopmental disorder with a high co-occurrence with intellectual disability. Adults with Autism and intellectual disability have a high incidence of challenging behaviour, defined as repetitive self injurious or aggressive behaviour. We underwent a systemic review of the evidence for treating challenging behaviours in adults with Autism and intellectual disability. Methods A literature search was conducted using three large databases to extract studies on the treatment of challenging behaviour among adults with Autism and intellectual disability. Papers, which met this criterion, were reviewed and analysed to assess study evidence and quality. Results Seven articles were selected which included five agents: fluvoxamine, sertraline, clomipramine, risperidone, and ziprasidone. Randomized control studies of fluvoxamine and risperidone, provided efficacy for the treatment of challenging behaviour in adults with Autism and intellectual disability. Open label trials of sertraline, clomipramine and ziprasidone were also effective in treating challenging behaviours for this population. Discussion Risperidone and fluvoxamine provided the best evidence for treating challenging behaviour, and risperidone was the only medication with multiple trials showing its efficacy. Further studies are required to demonstrate the efficacy of psychopharmacology in treating challenging behaviours among adults with Autism and intellectual disability. En ligne : http://dx.doi.org/10.1016/j.rasd.2014.03.021 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=233
in Research in Autism Spectrum Disorders > 8-7 (July 2014) . - p.803-813[article] Psychopharmacological treatment of challenging behaviours in adults with autism and intellectual disabilities: A systematic review [Texte imprimé et/ou numérique] / Amanda SAWYER, Auteur ; Johanna K. LAKE, Auteur ; Yona LUNSKY, Auteur ; Shi-Kai LIU, Auteur ; Pushpal DESARKAR, Auteur . - p.803-813.
Langues : Anglais (eng)
in Research in Autism Spectrum Disorders > 8-7 (July 2014) . - p.803-813
Mots-clés : Autism Adults Challenging behaviours Psychopharmacology Intellectual disability Index. décimale : PER Périodiques Résumé : AbstractIntroduction Autism is a neurodevelopmental disorder with a high co-occurrence with intellectual disability. Adults with Autism and intellectual disability have a high incidence of challenging behaviour, defined as repetitive self injurious or aggressive behaviour. We underwent a systemic review of the evidence for treating challenging behaviours in adults with Autism and intellectual disability. Methods A literature search was conducted using three large databases to extract studies on the treatment of challenging behaviour among adults with Autism and intellectual disability. Papers, which met this criterion, were reviewed and analysed to assess study evidence and quality. Results Seven articles were selected which included five agents: fluvoxamine, sertraline, clomipramine, risperidone, and ziprasidone. Randomized control studies of fluvoxamine and risperidone, provided efficacy for the treatment of challenging behaviour in adults with Autism and intellectual disability. Open label trials of sertraline, clomipramine and ziprasidone were also effective in treating challenging behaviours for this population. Discussion Risperidone and fluvoxamine provided the best evidence for treating challenging behaviour, and risperidone was the only medication with multiple trials showing its efficacy. Further studies are required to demonstrate the efficacy of psychopharmacology in treating challenging behaviours among adults with Autism and intellectual disability. En ligne : http://dx.doi.org/10.1016/j.rasd.2014.03.021 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=233 Annual Research Review: Defining and treating pediatric treatment-resistant depression / Jennifer B. DWYER in Journal of Child Psychology and Psychiatry, 61-3 (March 2020)
[article]
Titre : Annual Research Review: Defining and treating pediatric treatment-resistant depression Type de document : Texte imprimé et/ou numérique Auteurs : Jennifer B. DWYER, Auteur ; Argyris STRINGARIS, Auteur ; David A. BRENT, Auteur ; Michael H. BLOCH, Auteur Article en page(s) : p.312-332 Langues : Anglais (eng) Mots-clés : Depression major depressive disorder psychopharmacology psychotherapy Index. décimale : PER Périodiques Résumé : BACKGROUND: Adolescent major depressive disorder (MDD) is a significant health problem, associated with substantial morbidity, cost, and mortality. Depression is a significant risk factor for suicide, which is now the second leading cause of death in young people. Up to twenty per cent of adolescents will experience MDD before adulthood, and while a substantial proportion will improve with standard-of-care treatments (psychotherapy and medication), roughly one third will not. METHODS: Here, we have reviewed the literature in order to discuss the concept of treatment-resistant depression (TRD) in adolescence, examine risk factors, diagnostic difficulties, and challenges in evaluating symptom improvement, and providing guidance on how to define adequate medication and psychotherapy treatment trials. RESULTS: We propose a staging model for adolescent TRD and review the treatment literature. The evidence base for first- and second-line treatments primarily derives from four large pediatric clinical trials (TADS, TORDIA, ADAPT, and IMPACT). After two medications and a trial of evidence-based psychotherapy have failed to alleviate depressive symptoms, the evidence becomes quite thin for subsequent treatments. Here, we review the evidence for the effectiveness of medication switches, medication augmentation, psychotherapy augmentation, and interventional treatments (i.e., transcranial magnetic stimulation, electroconvulsive therapy, and ketamine) for adolescent TRD. Comparisons are drawn to the adult TRD literature, and areas for future pediatric depression research are highlighted. CONCLUSIONS: As evidence is limited for treatments in this population, a careful consideration of the known risks and side effects of escalated treatments (e.g., mood stabilizers and atypical antipsychotics) is warranted and weighed against potential, but often untested, benefits. En ligne : http://dx.doi.org/10.1111/jcpp.13202 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=420
in Journal of Child Psychology and Psychiatry > 61-3 (March 2020) . - p.312-332[article] Annual Research Review: Defining and treating pediatric treatment-resistant depression [Texte imprimé et/ou numérique] / Jennifer B. DWYER, Auteur ; Argyris STRINGARIS, Auteur ; David A. BRENT, Auteur ; Michael H. BLOCH, Auteur . - p.312-332.
Langues : Anglais (eng)
in Journal of Child Psychology and Psychiatry > 61-3 (March 2020) . - p.312-332
Mots-clés : Depression major depressive disorder psychopharmacology psychotherapy Index. décimale : PER Périodiques Résumé : BACKGROUND: Adolescent major depressive disorder (MDD) is a significant health problem, associated with substantial morbidity, cost, and mortality. Depression is a significant risk factor for suicide, which is now the second leading cause of death in young people. Up to twenty per cent of adolescents will experience MDD before adulthood, and while a substantial proportion will improve with standard-of-care treatments (psychotherapy and medication), roughly one third will not. METHODS: Here, we have reviewed the literature in order to discuss the concept of treatment-resistant depression (TRD) in adolescence, examine risk factors, diagnostic difficulties, and challenges in evaluating symptom improvement, and providing guidance on how to define adequate medication and psychotherapy treatment trials. RESULTS: We propose a staging model for adolescent TRD and review the treatment literature. The evidence base for first- and second-line treatments primarily derives from four large pediatric clinical trials (TADS, TORDIA, ADAPT, and IMPACT). After two medications and a trial of evidence-based psychotherapy have failed to alleviate depressive symptoms, the evidence becomes quite thin for subsequent treatments. Here, we review the evidence for the effectiveness of medication switches, medication augmentation, psychotherapy augmentation, and interventional treatments (i.e., transcranial magnetic stimulation, electroconvulsive therapy, and ketamine) for adolescent TRD. Comparisons are drawn to the adult TRD literature, and areas for future pediatric depression research are highlighted. CONCLUSIONS: As evidence is limited for treatments in this population, a careful consideration of the known risks and side effects of escalated treatments (e.g., mood stabilizers and atypical antipsychotics) is warranted and weighed against potential, but often untested, benefits. En ligne : http://dx.doi.org/10.1111/jcpp.13202 Permalink : https://www.cra-rhone-alpes.org/cid/opac_css/index.php?lvl=notice_display&id=420 Brief Report: Major Depressive Disorder with Psychotic Features in Williams Syndrome: A Case Series / F. VALDES in Journal of Autism and Developmental Disorders, 48-3 (March 2018)
PermalinkPractitioner Review: The effects of atypical antipsychotics and mood stabilisers in the treatment of depressive symptoms in paediatric bipolar disorder / Tobias ATKIN in Journal of Child Psychology and Psychiatry, 58-8 (August 2017)
PermalinkThe Variation of Psychopharmacological Prescription Rates for People With Autism Spectrum Disorder (ASD) in 30 Countries / Angel Y. S. WONG in Autism Research, 7-5 (October 2014)
Permalink